Meta-analysis of real-world survival outcomes of liposomal irinotecan in advanced pancreatic cancer patients with prior irinotecan exposure

被引：0
|
作者：
Gupta, A. [1 ]
Laheru, D. [1 ]
机构：
[1] Johns Hopkins Med, Sidney Kimmel Comprehens Canc Ctr, Med Oncol, Baltimore, MD USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2627
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1680P
引用
下载
收藏
页码：S921 / S921
页数：1
相关论文
共 50 条
  • [21] Multivariable analysis of real-world clinical outcomes associated with dose reductions (DRs) for patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan
    Abushahin, L.
    Cockrum, P.
    Surinach, A.
    Belanger, B.
    ANNALS OF ONCOLOGY, 2020, 31 : S943 - S944
  • [22] Is There Room for Liposomal Irinotecan in Biliary Tract Cancer? A Meta-analysis of Randomised Trials
    Merz, V.
    Messina, C.
    Zecchetto, C.
    Quinzii, A.
    Frisinghelli, M.
    Trentin, C.
    Salati, M.
    Caffo, O.
    Melisi, D.
    CLINICAL ONCOLOGY, 2024, 36 (02) : 87 - 97
  • [23] Are real-world patient-reported outcomes associated with survival in patients with advanced pancreatic cancer?
    Dai, Wei Fang
    Beca, Jaclyn Marie
    Guo, Helen
    Qiao, Lucy
    Isaranuwatchai, Wanrudee
    Schwartz, Deborah
    Naipaul, Rohini
    Arias, Jessica
    Gavura, Scott
    Barbera, Lisa Catherine
    Chan, Kelvin K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (30)
  • [24] Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group
    Yoo, Changhoon
    Im, Hyeon-Su
    Kim, Kyu-pyo
    Oh, Do-Youn
    Lee, Kyung-Hun
    Chon, Hong Jae
    Kim, Joo Hoon
    Kang, Myoungjoo
    Kim, Ilhwan
    Lee, Guk Jin
    Oh, Sung Yong
    Choi, Younak
    Choi, Hye Jin
    Kim, Seung Tae
    Park, Joon Oh
    Ryoo, Baek-Yeol
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [25] Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer
    Brendel, Karl
    Bekaii-Saab, Tanios
    Boland, Patrick M.
    Dayyani, Farshid
    Dean, Andrew
    Macarulla, Teresa
    Maxwell, Fiona
    Mody, Kabir
    Pedret-Dunn, Anna
    Wainberg, Zev A.
    Zhang, Bin
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2021, 10 (12): : 1550 - 1563
  • [26] Real-world survival outcomes in patients with advanced urothelial cancer in Germany
    Niegisch, G.
    Gerullis, H.
    Lin, S-W.
    Pavlova, J.
    Gondos, A.
    Rudolph, A.
    Haas, G.
    Hennies, N.
    Kramer, M. W.
    ANNALS OF ONCOLOGY, 2017, 28
  • [27] Efficacy and Safety of the Combination of Nano-Liposomal Irinotecan and 5-Fluorouracil/L-Leucovorin in Unresectable Advanced Pancreatic Cancer: A Real-World Study
    Yasuoka, Hidetoshi
    Naganuma, Atsushi
    Kurihara, Eishin
    Kobatake, Tsutomu
    Ijima, Masashi
    Tamura, Yuki
    Suzuki, Yuhei
    Hoshino, Takashi
    Ishida, Fumiya
    Hosaka, Hisashi
    Hatanaka, Takeshi
    Yoshida, Sachiko
    Aihara, Ryusuke
    Hosouchi, Yasuo
    Ishii, Norihiro
    Araki, Kenichiro
    Shirabe, Ken
    Uraoka, Toshio
    Kakizaki, Satoru
    ONCOLOGY, 2022, 100 (08) : 449 - 459
  • [28] Real-world dosing patterns of patients (pts) with metastatic pancreatic cancer (mPC) treated with liposomal irinotecan (nal-IRI) in US oncology clinics
    Ahn, D.
    Barzi, A.
    Miksad, R. A.
    Surinach, A.
    Corvino, F. A.
    Valderrama, A.
    Mamlouk, K.
    Pulgar, S.
    Bekaii-Saab, T.
    ANNALS OF ONCOLOGY, 2018, 29 : 251 - 251
  • [29] REAL-WORLD CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH METASTATIC DUCTAL ADENOCARCINOMA (MPDAC) TREATED WITH LIPOSOMAL IRINOTECAN-BASED REGIMENS BY RACE
    Kim, G. P.
    Cockrum, P.
    Lamarre, N.
    Surinach, A.
    VALUE IN HEALTH, 2021, 24 : S23 - S23
  • [30] A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid
    Kieler, Markus
    Unseld, Matthias
    Bianconi, Daniela
    Scheithauer, Werner
    Prager, Gerald W.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
12345